NEW YORK, Jan. 17, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Cintas Corporation (NASDAQ: CTAS)
Class Period: March 6, 2017 – November 13, 2019
Deadline: February 10, 2020
For more info: www.bgandg.com/ctas
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Cintas never tracked legacy margins following the G&K acquisition; (2) the Company has systematically provided guidance with which it would outperform (a “Beat and Raise” scheme); (3) undisclosed to the investing public, the Company has breached the law multiple times; (4) as a result of publicly known and undisclosed breaches of law, the Company’s Credit Agreement may be jeopardized; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Correvio Pharma Corp. (NASDAQ: CORV)
Class Period: October 23, 2018 – December 5, 2019
Deadline: February 10, 2020
For more info: www.bgandg.com/corv
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting the Resubmitted New Drug Application (“NDA”) for Brinavess did not minimize the significant health and safety issues observed in connection with the drug’s original NDA; (2) the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) as a result, Correvio’s public statements were materially false and misleading at all relevant times.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
Latest posts by GlobeNewswire (see all)
- Trustifi’s New OCR Tool Brings AI to Email Security, Auto-encrypting Sensitive Images - February 24, 2020
- Artelo Biosciences to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference - February 24, 2020
- Rosetta Stone’s Senior Director of EL Curriculum, Maya Goodall, to Host Upcoming SXSW EDU Session - February 24, 2020